Takahashi K, Nakamura A, Furusawa S, Yokozeki K, Sugawara H, Yanagisawa H, Akikawa K, Kikuchi H. Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria.
J Clin Transl Endocrinol, 2020 (in press).
IF：なし
Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, Kitagataya T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S and Sakamoto N for the NORTE Study Group.
Tenofovir disoproxil fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol, in press.
IF: 6.132
Favorable effect of sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on nonalcoholic fatty liver disease compared with pioglitazone.
Cho KY, Nakamura A, Omori K, Takase T, Miya A, Yamamoto K, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H Journal of Diabetes Investigation, in press.
IF 3.761
Miyoshi A, Kameda H, Nagai S, Nakamura A, Miya A, Takase T, Astumi T, Miyoshi H.
Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulator in postmenopausal women with type 2 diabetes and osteoporosis.
Journal of Diabetes Investigation, in press.
IF: 3.761
Naruse K, Abiko A, Nakayama H, Tanaka N, Ikeda K, Imachi H, Usigome E, Umayahara Y, Ota S, Okada Y, Kodani N, Takahashi N, Terai A, Nakamura A, Fujikawa R, Miura J, Morita E, Yanagimachi M, Ueki K on behalf of the Japan Diabetes Society Committee to Promote Female Diabetologists.
The work style and living condition survey of diabetologists and the expectations for the Japan Diabetes Society: results of questionnaires about the current state and the future prospect of their carrier in 2017.
Diabetol Int. 11:299–308, 2020
IF:なし
Aika Miya, Akinobu Nakamura, Takahisa Handa, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, So Nagai, Hideaki Miyoshi, Tatsuya Atsumi Impaired insulin secretion predicting unstable glycemic variability and Time-Below-Range in type 2 diabetes regardless of HbA1c or diabetes treatment Journal of Diabetes Investigation, in press.
IF: 3.761
Baba N, Kameda H, Nakamura A, Cho KY, Nomoto H, Mitsuhashi T, Miyoshi H, Atsumi T.
Silent pituitary adenoma and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dyslipidemia.
Endocrine Journal, in press.
IF: 1.952
Yanagiya S, Nakamura K, Ukawa S, Tsutsumi A, Atsumi T, Tamakoshi A.
Household income and the risk of incident hypertension in employees at multiple workplaces in Japan: J-HOPE.
Hypertens Res. 2020 Aug 24.
IF：2.941 (2019)
Chiho Oba-Yamamoto, Jun Takeuchi, Akinobu Nakamura, Ryoko Takikawa, Ayano Ozaki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, and Hideaki Miyoshi Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia J Diabetes Investig, in press
IF: 3.761
Koki Chiba, Hiroshi Nomoto, Akinobu Nakamura, Kyu Yong Cho, Kumiko Yamashita, Yui Shibayama, Aika Miya, Hiraku Kameda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi. SGLT2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes.
J Diabetes Investig, in press
IF: 3.761
